Results 41 to 50 of about 42,252 (217)

Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies

Scientific Reports, 2018
Nucleolin arises as a relevant target for cancer therapy, as it is overexpressed at the surface of cancer and angiogenic endothelial cells thus enabling a dual cellular targeting strategy.
Sofia Romano, Vera Moura, Sérgio Simões, João Nuno Moreira, João Gonçalves   +4 more
doaj   +1 more source

Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies

mAbs, 2021
The respiratory virus responsible for coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life worldwide, claiming the lives of over 3.9 million people globally, at the ...
Maxwell A. Stefan, Yooli K. Light, Jennifer L. Schwedler, Peter R. McIlroy, Colleen M. Courtney, Edwin A. Saada, Christine E. Thatcher, Ashlee M. Phillips, Feliza A. Bourguet, Catherine M. Mageeney, Summer A. McCloy, Nicole M. Collette, Oscar A. Negrete, Joseph S. Schoeniger, Dina R. Weilhammer, Brooke Harmon   +15 more
doaj   +1 more source

Contribution of CDR3 in characterization of camelid VHH and its aflatoxin B1-binding interaction

Food Chemistry Advances
The single variable domain of heavy chain (VHH) antibodies, owing to their unique properties, has gained attention in immunoassays. However, compared with macromolecule antigens, in the case of small molecule haptens, such as aflatoxin B1 (AFB1), the ...
Hina Mukhtar, Lan Ma, Qian Pang, Xiaohong Wang, Jia Wang   +4 more
doaj   +1 more source

Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell Lines

BIO Integration
Background: Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor. Cell and gene therapy, which offer many advantages in treating BLCA, are urgently needed.
Jinping Niu, Guodi Liu, Sai Zhang, Chengnan Xu, Ziwen Xu, Xingyuan Ma, Xiaoli Tian, Wenyun Zheng   +7 more
doaj   +1 more source

Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants

Frontiers in Immunology, 2022
Anti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants.
Qi Li, Fiachra Humphries, Roxie C. Girardin, Aaron Wallace, Monir Ejemel, Alla Amcheslavsky, Conor T. McMahon, Zachary A. Schiller, Zepei Ma, John Cruz, Alan P. Dupuis, Anne F. Payne, Arooma Maryam, Nese Kurt Yilmaz, Kathleen A. McDonough, Brian G. Pierce, Celia A. Schiffer, Andrew C. Kruse, Mark S. Klempner, Lisa A. Cavacini, Katherine A. Fitzgerald, Yang Wang   +21 more
doaj   +1 more source

Intracellular VHHs to monitor and modulate GPCR signaling

Frontiers in Endocrinology, 2022
Single-domain antibody fragments, also known as VHHs or nanobodies, have opened promising avenues in therapeutics and in exploration of intracellular processes. Because of their unique structural properties, they can reach cryptic regions in their cognate antigen.
Pauline Raynaud, Camille Gauthier, Vinesh Jugnarain, Frédéric Jean-Alphonse, Frédéric Jean-Alphonse, Eric Reiter, Eric Reiter, Gilles Bruneau, Pascale Crépieux, Pascale Crépieux   +9 more
openaire   +5 more sources

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

OncoImmunology, 2018
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy.
Renée C. G. de Bruin, John P. Veluchamy, Sinéad M. Lougheed, Famke L. Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G. Stam, Zsolt Sebestyen, Jürgen Kuball, Carla F. M. Molthoff, Erik Hooijberg, Rob C. Roovers, James P. Di Santo, Paul M. P. van Bergen en Henegouwen, Henk M. W. Verheul, Tanja D. de Gruijl, Hans J. van der Vliet   +16 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Anticuerpos de cadena única de alpaca para la detección de antígenos de Fasciola hepatica

Revista Peruana de Medicina Experimental y Salud Pública, 2018
Objetivo. Producir anticuerpos recombinantes de cadena única de alpaca que se unan con alta afinidad y especificidad al antígeno excretado-secretado (ES) de Fasciola hepatica para el desarrollo de tecnologías nuevas de diagnóstico de fascioliasis humana ...
Teresa Barreto, Yenisey Alfonso, Pierre Lafaye, Maria del Pilar García Lazaro, L. Agueda Perez, Patricia Herrera-Velit, Jose R. Espinoza   +6 more
doaj   +1 more source

Anti-idiotypic VHH mediated environmentally friendly immunoassay for citrinin without mycotoxin

Food and Agricultural Immunology, 2020
Competitive enzyme-linked immunosorbent assay (ELISA) is the most widely used method for rapidly screening of mycotoxins in contaminated food products; however, it involves the use of toxin-protein conjugates as a competitive antigen and toxin standards ...
Liang Xiong, Xueqin Zhang, Yang Xu, Yanping Li, Deguang Liu, Zhui Tu, Qinghua He   +6 more
doaj   +1 more source